OpenURL Connection Search

Select item for more details and to access through your institution.

Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments.
Published in:
Frontiers in Psychiatry, 2021, v. 12, p. 1, doi. 10.3389/fpsyt.2021.722378
By:
- Verdura, Edgard;
- Pérez-Cano, Laura;
- Sabido-Vera, Rubén;
- Guney, Emre;
- Hyvelin, Jean-Marc;
- Durham, Lynn;
- Gomez-Mancilla, Baltazar
Publication type:
Article
Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.
Published in:
Frontiers in Health Services, 2024, p. 1, doi. 10.3389/frhs.2024.1254294
By:
- Hoin, Jon A.;
- Carthon, Bradley C.;
- Brown, Shantoria J.;
- Durham, Lynn M.;
- Garrot, L. Crain;
- Ghamande, Sharad A.;
- Pippas, Andrew W.;
- Rivers, Brian M.;
- Snyder, Cindy T.;
- Gabram-Mendola, Sheryl Gordon Ann
Publication type:
Article
Screening for Individuals at Risk for Hereditary Breast and Ovarian Cancer: A Statewide Initiative, Georgia, 2012–2020.
Published in:
American Journal of Public Health, 2022, v. 112, n. 9, p. 1249, doi. 10.2105/ajph.2022.306932
By:
- Veitinger, Julia K.;
- Kerber, Alice S.;
- Gabram-Mendola, Sheryl G. A.;
- Liu, Yuan;
- Durham, Lynn M.;
- Durrence, Diane;
- Berzen, Alissa K.;
- Shin, Janet Y.;
- Snyder, Cindy;
- Bellcross, Cecelia A.;
- Guan, Yue
Publication type:
Article
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD.
Published in:
Biomedicines, 2024, v. 13, n. 7, p. 1430, doi. 10.3390/biomedicines12071430
By:
- Erickson, Craig A.;
- Perez-Cano, Laura;
- Pedapati, Ernest V.;
- Painbeni, Eric;
- Bonfils, Gregory;
- Schmitt, Lauren M.;
- Sachs, Hannah;
- Nelson, Meredith;
- De Stefano, Lisa;
- Westerkamp, Grace;
- de Souza, Adriano L. S.;
- Pohl, Oliver;
- Laufer, Offir;
- Issachar, Gil;
- Blaettler, Thomas;
- Hyvelin, Jean-Marc;
- Durham, Lynn A.
Publication type:
Article
Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment.
Published in:
Biomedicines, 2024, v. 12, n. 5, p. 991, doi. 10.3390/biomedicines12050991
By:
- Pérez-Cano, Laura;
- Boccuto, Luigi;
- Sirci, Francesco;
- Hidalgo, Jose Manuel;
- Valentini, Samuel;
- Bosio, Mattia;
- Liogier D'Ardhuy, Xavier;
- Skinner, Cindy;
- Cascio, Lauren;
- Srikanth, Sujata;
- Jones, Kelly;
- Buchanan, Caroline B.;
- Skinner, Steven A.;
- Gomez-Mancilla, Baltazar;
- Hyvelin, Jean-Marc;
- Guney, Emre;
- Durham, Lynn
Publication type:
Article

Found: 5

Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments.

Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.

Screening for Individuals at Risk for Hereditary Breast and Ovarian Cancer: A Statewide Initiative, Georgia, 2012–2020.

Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD.

Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment.